Associations of components of PTEN/AKT/mTOR pathway with cancer stem cell markers and prognostic value of these biomarkers in hepatocellular carcinoma

Hepatology Research

Volumn 46, Issue 13, 2016, Pages 1380-1391

  Su, Rujuan ^a   Nan, Haocheng ^a   Guo, Hui ^a   Ruan, Zhiping ^a   Jiang, Lili ^a   Song, Yuanyuan ^a   Nan, Kejun ^a  

^a THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

AKT; cancer stem cell; hepatocellular carcinoma; mammalian target of rapamycin; PTEN

Indexed keywords

CD133 ANTIGEN; EPITHELIAL CELL ADHESION MOLECULE; HERMES ANTIGEN; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; THY 1 ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER STEM CELL; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECURRENCE FREE SURVIVAL; SURVIVAL PREDICTION;

EID: 84962809934     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12687     Document Type: Article

References (43)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69–90.
2. Nguyen LV, Vanner R, Dirks P, Eaves CJ. Cancer stem cells: an evolving concept. Nat Rev Cancer 2012; 12: 133–43.
3. Boman BM, Wicha MS. Cancer stem cells: a step toward the cure. J Clin Oncol 2008; 26: 2795–9.
4. Badve S, Nakshatri H. Breast-cancer stem cells – beyond semantics. Lancet Oncol 2012; 13: e43–8.
5. Lonardo E, Hermann PC, Heeschen C. Pancreatic cancer stem cells – update and future perspectives. Mol Oncol 2010; 4: 431–42.
6. Wang R, Chadalavada K, Wilshire J et al. Glioblastoma stem-like cells give rise to tumour endothelium. Nature 2010; 468: 829–33.
7. Sainz B Jr, Heeschen C. Standing out from the crowd: cancer stem cells in hepatocellular carcinoma. Cancer Cell 2013; 23: 431–3.
8. Karnoub AE, Dash AB, Vo AP et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007; 449: 557–63.
9. Ricci-Vitiani L, Pallini R, Biffoni M et al. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 2010; 468: 824–8.
10. Wicha MS. Targeting self-renewal, an Achilles’ heel of cancer stem cells. Nat Med 2014; 20: 14–58.
11. Terris B, Cavard C, Perret C. EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma. J Hepatol 2010; 52: 280–1.
12. Yamashita T, Ji J, Budhu A et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 2009; 136: 1012–24.
13. Marquardt JU, Factor VM, Thorgeirsson SS. Epigenetic regulation of cancer stem cells in liver cancer: current concepts and clinical implications. J Hepatol 2010; 53: 568–77.
14. Li L, Hao X, Qin J et al. Antibody against CD44s inhibits pancreatic tumor initiation and postradiation recurrence in mice. Gastroenterology 2014; 146: 1108–18.
15. Yang ZF, Ho DW, Ng MN et al. Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell 2008; 13: 153–66.
16. Ma S, Tang KH, Chan YP et al. miR-130b promotes CD133(+) liver tumor-initiating cell growth and selfrenewal via tumor protein 53-induced nuclear protein 1. Cell Stem Cell 2010; 7: 694–707.
17. Yamashita T, Forgues M, Wang W et al. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res 2008; 68: 1451–61.
18. Valent P, Bonnet D, De Maria R et al. Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer 2012; 12: 767–75.
19. Ma S, Chan KW, Hu L et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 2007; 132: 2542–56.
20. Liu LL, Fu D, Ma Y, Shen XZ. The power and the promise of liver cancer stem cell markers. Stem Cells Dev 2011; 20: 2023–30.
21. Xia H, Ooi LL, Hui KM. MicroRNA-216a/217-induced epithelial–mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer. Hepatol 2013; 58: 629–41.
22. Chen JS, Wang Q, Fu XH et al. Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: association with MMP-9. Hepatol Res 2009; 39: 177–86.
23. Cheng RB, Ma RJ, Wang ZK et al. PTEN status is related to cell proliferation and self-renewal independent of CD133 phenotype in the glioma-initiating cells. Mol Cell Biochem 2011; 349: 149–57.
24. Tian T, Nan KJ, Wang SH et al. PTEN regulates angiogenesis and VEGF expression through phosphatase-dependent and -independent mechanisms in HepG2 cells. Carcinogenesis 2010; 31: 1211–9.
25. Song BQ, Chi Y, Li X et al. Inhibition of Notch signaling promotes the adipogenic differentiation of mesenchymal stem cells through autophagy activation and PTEN-PI3K/AKT/mTOR pathway. Cell Physiol Biochem 2015; 36(5): 1991–2002.
26. Lyu J, Yu X, He L et al. The protein phosphatase activity of PTEN is essential for regulating neural stem cell differentiation. Mol Brain 2015; 8: 26.
27. Choorapoikayil S, Kers R, Herbomel P, Kissa K, den Hertog J. Pivotal role of Pten in the balance between proliferation and differentiation of hematopoietic stem cells in zebrafish. Blood 2014; 123: 184–90.
28. Lee TK, Castilho A, Cheung VC, Tang KH, Ma S, Ng IO. Lupeol targets liver tumor-initiating cells through phosphatase and tensin homolog modulation. Hepatology 2011; 53: 160–70.
29. Ruan ZP, Xu R, Lv Y et al. PTEN enhances the sensitivity of human hepatocellular carcinoma cells to sorafenib. Oncol Res 2012; 20: 113–21.
30. Kreso A, van Galen P, Pedley NM et al. Self-renewal as a therapeutic target in human colorectal cancer. Nat Med 2014; 20: 29–36.
31. Yu Y, Nangia-Makker P, Farhana LG, Rajendra S, Levi E, Majumdar AP. miR-21 and miR-145 cooperation in regulation of colon cancer stem cells. Mol Cancer 2015; 14: 98.
32. Sun C, Zhao J, Jin Y et al. PTEN regulation of the proliferation and differentiation of auditory progenitors through the PTEN/PI3K/Akt-signaling pathway in mice. Neuroreport 2014; 25: 177–83.
33. He X, Cao Y, Wang L et al. Human fibroblast reprogramming to pluripotent stem cells regulated by the miR19a/b-PTEN axis. PLoS One 2014; 9: e95213.
34. Huang J, Yuan SX, Wang DX et al. The role of COX-2 in mediating the effect of PTEN on BMP9 induced osteogenic differentiation in mouse embryonic fibroblasts. Biomaterials 2014; 35: 9649–59.
35. Mulholland DJ, Tran LM, Li Y et al. Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell 2011; 19: 792–804.
36. Gont A, Hanson JE, Lavictoire SJ et al. PTEN loss represses glioblastoma tumor initiating cell differentiation via inactivation of Lgl1. Oncotarget 2013; 4: 1266–79.
37. Xia P, Xu XY. PI3K/AKT/mTOR signaling pathway in cancer stem cells: from basic research to clinical application. Am J Cancer Res 2015; 5: 1602–9.
38. Yang XR, Xu Y, Yu B et al. High expression levels of putative hepatic stem/progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma. Gut 2010; 59: 953–62.
39. Kohga K, Tatsumi T, Takehara T et al. Expression of CD133 confers malignant potential by regulating metalloproteinases in human hepatocellular carcinoma. J Hepatol 2010; 52: 872–9.
40. Salnikov AV, Kusumawidjaja G, Rausch V et al. Cancer stem cell marker expression in hepatocellular carcinoma and liver metastases is not sufficient as single prognostic paramater. Cancer Lett 2008; 275: 185–93.
41. Sun YF, Xu Y, Yang XR et al. Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection. Hepatol 2013; 57: 1458–68.
42. Yamashita T, Honda M, Nakamoto Y et al. Discrete nature of EpCAM+ and CD90+ cancer stem cells in human hepatocellular carcinoma. Hepatology 2013; 57: 1484–97.
43. Wilson GS, Hu Z, Duan W et al. Efficacy of using cancer stem cell markers in isolating and characterizing liver cancer stem cells. Stem Cells Dev 2013; 22: 2655–64.